167 related articles for article (PubMed ID: 27161435)
1. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
[No Abstract] [Full Text] [Related]
2. Clinicopathologic correlates of
Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
[TBL] [Abstract][Full Text] [Related]
3. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.
Poulain S; Boyle EM; Tricot S; Demarquette H; Doye E; Roumier C; Duthilleul P; Preudhomme C; Maurage CA; Morschhauser F
Br J Haematol; 2015 Jul; 170(2):285-7. PubMed ID: 25643939
[No Abstract] [Full Text] [Related]
4. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
[No Abstract] [Full Text] [Related]
5. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
6. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Bromberg JEC; Nierkens S; Jiwa NM; Minnema MC; Huibers MMH
Br J Haematol; 2019 Jun; 185(5):974-977. PubMed ID: 30408153
[No Abstract] [Full Text] [Related]
7. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
8. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
[TBL] [Abstract][Full Text] [Related]
10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
Lee JH; Jeong H; Choi JW; Oh H; Kim YS
Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
13. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
14. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
[TBL] [Abstract][Full Text] [Related]
15. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
18. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
19. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
20. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
